ESMO Breast 2022 | monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC

Nadia Harbeck, MD, PhD, Ludwig Maximilians University – Grosshadern, Munich, Germany, reports on the efficacy and safety by menopausal status from the Phase III monarchE (NCT03155997) trial investigating adjuvant abemaciclib combined with endocrine therapy in patients with HR-positive, HER2-negative high-risk early breast cancer. Endocrine therapy consisted of tamoxifen or an aromatase inhibitor (AI), with or without additional GnRH as determined by the physician. The treatment benefit was similar across both menopausal status groups. In premenopausal woman, more thrombotic events were observed than we AI and GnRH. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.